Table 5.
Clinical information, cytomorphologic type, TNM staging, and response to treatment with VCR-LAP protocol.
| No. | Age (year) | Sex | Type | Area of lesion | Cytomorphologic type | TNM stage | Treatment time (responsive) | General sign/lethargy | Weight loss | GI toxicity | Hematologic toxicity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3 | M | GTVT | Penis | Plasmacytic | T3 | 3 weeks (CR) | G0 | G1 | G0 | G0 |
| 2 | 2 | M | GTVT | Penis | Plasmacytic | T2 | 4 weeks (CR) | G0 | G1 | G0 | G0 |
| 3 | 2 | F | GTVT | Vulva and vagina | Plasmacytic | T3 | 3 weeks (CR) | G0 | G1 | G0 | G0 |
| 4 | 2 | M | GTVT | Penis | Plasmacytic | T3 | 2 weeks (CR) | G0 | G0 | G0 | G0 |
| 5 | 5 | F | GTVT | Vulva and vagina | Plasmacytic | T3 | 2 weeks (CR) | G0 | G0 | G0 | G0 |
| 6 | 1 | F | GTVT | Vulva and vagina | Mixed | T2 | 3 weeks (CR) | G1 | G0 | G1 | G0 |
| 7 | 4 | M | GTVT | Penis | Plasmacytic | T3 | 4 weeks (CR) | G0 | G0 | G0 | G0 |
| 8 | 9 | M | ETVT | Skin | Plasmacytic | T3N1M | 2 weeks (death) | G1 | G3 | G2 | G0 |
| 9 | 5 | M | ETVT | Skin and LN | Plasmacytic | T2N1M | 2 weeks (CR) | G0 | G0 | G0 | G0 |
| 10 | 3 | F | ETVT | Skin, vulva, and vagina | Plasmacytic | T3N1M | 3 weeks (CR) | G0 | G1 | G1 | G0 |
| 11 | 4 | M | ETVT | Skin, penis, and LN | Lymphocytic | T3N1M | 2 weeks (CR) | G0 | G1 | G0 | G0 |
| 12 | 4 | M | ETVT | Skin | Plasmacytic | T3 | 5 weeks (CR) | G0 | G0 | G1 | G0 |
| 13 | 3 | M | ETVT | Skin and penis | Plasmacytic | T3N0M | 5 weeks (CR) | G0 | G1 | G0 | G0 |
F, female; M, male; GTVT, genital canine transmissible venereal tumor; ETVT, extragenital canine transmissible venereal tumor; LN, lymph node; T, tumor; N, lymph node; M, metastasis; CR, complete response; PR, partial response; G, grade.